MCID: TRM003
MIFTS: 54

Tremor

Categories: Genetic diseases, Muscle diseases, Neuronal diseases, Oral diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Tremor

Summaries for Tremor

MedlinePlus: 41 What is a tremor? A tremor is a rhythmic shaking movement in one or more parts of your body. It is involuntary, meaning that you cannot control it. This shaking happens because of muscle contractions. A tremor is most often in your hands, but it could also affect your arms, head, vocal cords, trunk, and legs. It may come and go, or it may be constant. Tremor can happen on its own or be caused by another disorder. What are the types of tremor? There are several types of tremor, including: Essential tremor, sometimes called benign essential tremor. This is the most common type. It usually affects your hands, but it can also affect your head, voice, tongue, legs, and trunk. Parkinsonian tremor, which is a common symptom in people who have Parkinson's disease. It is usually affects one or both hands when they are at rest, but it can affect the chin, lips, face, and legs. Dystonic tremor, which happens in people who have dystonia. Dystonia is a movement disorder in which you have involuntary muscle contractions. The contractions cause you to have twisting and repetitive movements. It can affect any muscle in the body. What causes tremor? Generally, tremor is caused by a problem in the deep parts of the brain that control movements. For most types, the cause is unknown. Some types are inherited and run in families. There can also be other causes, such as: Neurologic disorders, including multiple sclerosis, Parkinson's disease, stroke, and traumatic brain injury Certain medicines, such as asthma medicines, amphetamines, caffeine, corticosteroids, and medicines used for certain psychiatric and neurological disorders Alcohol use disorder or alcohol withdrawal Mercury poisoning Hyperthyroidism (overactive thyroid) Liver or kidney failure Anxiety or panic Who is at risk for tremor? Anyone can get tremor, but it is most common in middle-aged and older adults. For certain types, having a family history raises your risk of getting it. What are the symptoms of tremor? Symptoms of tremor may include: Rhythmic shaking in the hands, arms, head, legs, or torso Shaky voice Difficulty writing or drawing Problems holding and controlling utensils, such as a spoon How is tremor diagnosed? Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms A physical exam, which includes checking Whether the tremor happens when the muscles are at rest or in action The location of the tremor How often you have the tremor and how strong it is A neurological exam, including checking for Problems with balance Problems with speech Increased muscle stiffness Blood or urine tests to look for the cause Imaging tests to help figure out if the cause is damage in your brain Tests which check your abilities to do daily tasks such as handwriting and holding a fork or cup An electromyogram, a test which measures involuntary muscle activity and how your muscles respond to nerve stimulation What are the treatments for tremor? There is no cure for most forms of tremor, but there are treatments to help manage symptoms. In some cases, the symptoms may be so mild that you do not need treatment. Finding the right treatment depends on getting the right diagnosis of the cause. Tremor caused by another medical condition may get better or go away when you treat that condition. If your tremor is caused by a certain medicine, stopping that medicine usually makes the tremor go away. Treatments for tremor where the cause is not found include: Medicines. There are different medicines for the specific types of tremor. Another option is Botox injections, which can treat several different types. Surgery may be used for severe cases that do not get better with medicines. The most common type is deep brain stimulation (DBS). Physical, speech-language, and occupational therapy, which may help to control tremor and deal with the daily challenges caused by the tremor If you find that caffeine and other stimulants trigger your tremors, it may be helpful to cut them from your diet. NIH: National Institute of Neurological Disorders and Stroke

MalaCards based summary: Tremor, also known as medication-induced postural tremor, is related to tremor, hereditary essential, 1 and fragile x-associated tremor/ataxia syndrome. An important gene associated with Tremor is STXBP1 (Syntaxin Binding Protein 1), and among its related pathways/superpathways are Neuroscience and Parkinson's disease pathway. The drugs Propranolol and Pregabalin have been mentioned in the context of this disorder. Affiliated tissues include brain, thyroid and subthalamic nucleus, and related phenotypes are Increased shRNA abundance (Z-score > 2) and nervous system

NINDS: 52 Tremor is an unintentional, rhythmic, muscle movement involving to-and-fro movements of one or more parts of the body. Most tremors occur in the hands, although they can also affect the arms, head, face, voice, torso, and legs. Tremor may occur at separate times or be constant. There are two main categories of tremor: Resting tremor occurs when the muscle is relaxed, such as when the hands are resting on the lap Action tremor occurs with the intended movement of a muscle There are more than 20 types of tremor.  Some of the most common are: Essential tremor usually appears on both sites of the body and is often noticed more in the dominant hand Dystonic tremor can affect any muscle in the body and usually is associated with abnormal body postures due to forceful muscle spasms or cramps Parkinsonian tremor, with shaking of one or both hands at rest and may also affect the lips, face, and legs Generally, tremor is caused by a problem in the deep parts of the brain that control movements. Some forms of tremor are inherited and run in families, while others have no known cause. Sometimes tremor is a symptom of another neurological disorder or a side effect of certain drugs, but the most common form occurs in otherwise healthy people. Other causes of tremor can include the use of certain medicines, alcohol use disorder or withdrawal, and an overactive thyroid. Tremor may occur at any age but is most common in middle-aged and older adults.

Wikipedia: 75 A tremor is an involuntary, somewhat rhythmic, muscle contraction and relaxation involving oscillations... more...

Related Diseases for Tremor

Diseases in the Tremor family:

Tremor, Hereditary Essential, 1 Tremor, Hereditary Essential, 2
Tremor, Hereditary Essential, 3 Tremor, Hereditary Essential, 4
Tremor, Hereditary Essential, 5 Tremor, Hereditary Essential, 6
Essential Tremor Rare Tremor Disorder

Diseases related to Tremor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1034)
# Related Disease Score Top Affiliating Genes
1 tremor, hereditary essential, 1 33.0 TENM4 DRD3
2 fragile x-associated tremor/ataxia syndrome 32.9 FUS FRAXA FMR1
3 fragile x tremor/ataxia syndrome 32.8 FRAXA FMR1
4 tremor, hereditary essential, 4 32.7 TENM4 FUS
5 essential tremor 32.6 TENM4 SNCA PRKN NOTCH2NLC LRRK2 GBA1
6 parkinson disease 2, autosomal recessive juvenile 31.9 SNCA PRKN LRRK2
7 spinal and bulbar muscular atrophy, x-linked 1 31.8 SNCA FUS FMR1
8 parkinson disease 21 31.8 PRKN LRRK2
9 multiple system atrophy 1 31.8 SNCA PRKN LRRK2 GBA1 FMR1
10 parkinson disease 3, autosomal dominant 31.8 SNCA PRKN LRRK2
11 parkinson disease 1, autosomal dominant 31.8 SNCA LRRK2 GBA1
12 amyotrophic lateral sclerosis-parkinsonism/dementia complex 1 31.7 SNCA LRRK2 FUS
13 dystonia 31.7 SNCA PRKN LRRK2 DRD3 C19orf12
14 parkinson disease 4, autosomal dominant 31.6 SNCA GBA1
15 parkinson disease 15, autosomal recessive early-onset 31.6 SNCA PRKN LRRK2 C19orf12
16 parkinson disease, late-onset 31.5 SNCA PRKN LRRK2 LOC106627981 GBA1 FUS
17 cerebellar disease 31.2 SNCA PRKN LRRK2 FUS FMR1
18 movement disease 31.1 SNCA PRKN LRRK2 LOC106627981 GBA1 FUS
19 dementia, lewy body 31.1 SNCA PRKN LRRK2 LOC106627981 GBA1 FUS
20 hereditary late-onset parkinson disease 31.0 SNCA LRRK2 LOC106627981 GBA1
21 kufor-rakeb syndrome 31.0 SNCA PRKN LRRK2 GBA1 C19orf12
22 parkinsonism 30.9 SNCA PRKN LRRK2 LOC106627981 GBA1 FMR1
23 hereditary ataxia 30.9 SNCA PRKN FUS FMR1
24 autosomal dominant cerebellar ataxia 30.9 SNCA PRKN LRRK2 FUS FMR1
25 choreatic disease 30.8 SNCA PRKN LRRK2
26 charcot-marie-tooth disease, demyelinating, type 1c 30.8 MPZ FIG4
27 supranuclear palsy, progressive, 1 30.8 SNCA PRKN LRRK2 GBA1 FUS
28 restless legs syndrome 30.7 SNCA PRKN FRAXA FMR1 DRD3
29 rem sleep behavior disorder 30.6 SNCA PRKN LRRK2 GBA1
30 toxic encephalopathy 30.6 SNCA PRKN LRRK2
31 sleep disorder 30.5 SNCA LRRK2 GBA1
32 aphasia 30.4 SNCA LRRK2 FUS
33 frontotemporal dementia 30.4 SNCA PRKN LRRK2 FUS
34 vascular parkinsonism 30.3 SNCA PRKN LRRK2 GBA1
35 amyotrophic lateral sclerosis 1 30.3 SNCA PRKN LRRK2 GBA1 FUS FMR1
36 motor neuron disease 30.0 SNCA PRKN MPZ FUS
37 polyneuropathy 29.9 SNCA PRKN MT-ATP6 MPZ
38 pick disease of brain 29.9 SNCA PRKN LRRK2 FUS
39 aceruloplasminemia 29.9 STXBP1 SNCA MT-ATP6 HARS1 C19orf12
40 postencephalitic parkinson disease 29.8 SNCA PRKN LRRK2
41 progressive myoclonus epilepsy 29.8 STXBP1 SNCA GBA1
42 speech disorder 29.8 LOC106627981 GBA1 FMR1
43 early-onset parkinson's disease 29.8 SNCA PRKN LRRK2 GBA1 C19orf12
44 early myoclonic encephalopathy 29.8 STXBP1 MT-ATP6 GBA1
45 pseudobulbar palsy 29.7 SNCA FUS
46 autism spectrum disorder 29.6 STXBP1 SNCA PRKN FUS FMR1 DRD3
47 niemann-pick disease 29.6 SNCA MPZ GBA1
48 dementia 29.5 SNCA PRKN MT-ATP6 LRRK2 LOC106627981 GBA1
49 peripheral nervous system disease 29.3 SNCA PRKN MT-ATP6 MPZ LRRK2 HARS1
50 autism 29.3 STXBP1 SNCA PRKN FUS FMR1 DRD3

Graphical network of the top 20 diseases related to Tremor:



Diseases related to Tremor

Symptoms & Phenotypes for Tremor

GenomeRNAi Phenotypes related to Tremor according to GeneCards Suite gene sharing:

25 (show all 17)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.58 HARS1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-106 9.58 GBA1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-147 9.58 GBA1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.58 HARS1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.58 DRD3 HARS1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-182 9.58 GBA1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-204 9.58 HARS1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-213 9.58 HARS1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.58 DRD3
10 Increased shRNA abundance (Z-score > 2) GR00366-A-41 9.58 HARS1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-48 9.58 HARS1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.58 HARS1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-51 9.58 HARS1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.58 HARS1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.58 HARS1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-58 9.58 DRD3
17 Increased shRNA abundance (Z-score > 2) GR00366-A-98 9.58 HARS1

MGI Mouse Phenotypes related to Tremor:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.73 DRD3 FIG4 FMR1 FUS GBA1 LRRK2
2 behavior/neurological MP:0005386 9.44 AGO1 DRD3 FIG4 FMR1 FUS GBA1

Drugs & Therapeutics for Tremor

Drugs for Tremor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 100)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Propranolol Approved, Investigational Phase 4 318-98-9, 525-66-6 62882 4946
2
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
3
Memantine Approved, Investigational Phase 4 41100-52-1, 19982-08-2 4054
4
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
5
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
6
Ondansetron Approved, Withdrawn Phase 4 99614-02-5 4595
7
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
8
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643
9 Adrenergic beta-Antagonists Phase 4
10 Adrenergic Antagonists Phase 4
11 Anti-Arrhythmia Agents Phase 4
12 Antihypertensive Agents Phase 4
13 Vasodilator Agents Phase 4
14 Anticonvulsants Phase 4
15 Anti-Infective Agents Phase 4
16 Anti-Infective Agents, Local Phase 4
17 Excitatory Amino Acid Antagonists Phase 4
18 Botulinum Toxins Phase 4
19 Cholinergic Agents Phase 4
20
abobotulinumtoxinA Phase 4
21 Botulinum Toxins, Type A Phase 4
22 Dermatologic Agents Phase 4
23 Psychotropic Drugs Phase 4
24 Gastrointestinal Agents Phase 4
25 Anti-Anxiety Agents Phase 4
26 Antipsychotic Agents Phase 4
27 Antiemetics Phase 4
28
Triamcinolone hexacetonide Phase 4
29
Triamcinolone diacetate Phase 4
30
Triamcinolone Acetonide Phase 4 6436
31 Calcineurin Inhibitors Phase 4
32 Immunosuppressive Agents Phase 4
33 Immunologic Factors Phase 4
34 Liver Extracts Phase 4
35
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
36
Topiramate Approved Phase 3 97240-79-4 5284627
37
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
38
Tannic acid Approved Phase 3 1401-55-4 16129878 16129778
39
Ethanol Approved Phase 2, Phase 3 64-17-5 702
40
Sodium oxybate Approved Phase 2, Phase 3 502-85-2 23663870
41 Hypoglycemic Agents Phase 3
42 Anesthetics, Intravenous Phase 2, Phase 3
43 Anesthetics, General Phase 2, Phase 3
44
Eltanolone Approved, Investigational Phase 2 516-54-1, 128-20-1 31402 92786
45
Cannabidiol Approved, Investigational Phase 1, Phase 2 13956-29-1 521372 644019
46
Dronabinol Approved, Illicit Phase 1, Phase 2 1972-08-3 16078
47
Levetiracetam Approved Phase 1, Phase 2 102767-28-2 441341 5284583
48
Progesterone Approved, Vet_approved Phase 2 57-83-0 5994
49 Strawberry Approved Phase 2
50
Sage Approved Phase 2

Interventional clinical trials:

(show top 50) (show all 281)
# Name Status NCT ID Phase Drugs
1 Propranolol and Botulinum Toxin for Essential Vocal Tremor Completed NCT02111369 Phase 4 Propranolol
2 Functional Imaging of Tremor Circuits and Mechanisms of Treatment Response Completed NCT02495883 Phase 4 Propranolol
3 A Pilot Clinical Trial of Memantine for Essential Tremor Completed NCT00439699 Phase 4 Memantine
4 A Multi-site, Double-blind, Randomized, Placebo-controlled, Crossover Study of Pregabalin (Lyrica, PGB) in the Treatment of Essential Tremor Completed NCT00584376 Phase 4 Pregabalin;Placebo
5 RECHARGE Sub-Study to the Implantable Systems Performance Registry (ISPR) Completed NCT00998660 Phase 4
6 Treatment of Pendular Nystagmus With Gabapentin and Memantine in Patients With Oculopalatal Tremor: a Controled Open-label Study Completed NCT02466191 Phase 4 Memantine;Gabapentin
7 A Placebo-controlled, Double-blind, Randomized, Cross Over Pilot Study of the Efficacy and Tolerability of Abobotulinum Toxin A (Dysport) as a Treatment for Task-dependent Upper Limb Tremor Recruiting NCT03136341 Phase 4 Abobotulinum toxin A
8 A Pilot Study to Evaluate Impact on Neurological Side Effects (Cognition, Memory, and Tremor) in Elderly (Age>65) Patients Recruiting NCT03461445 Phase 4 Envarsus;IR Tacrolimus
9 Does Higher Operation Theatre Ambient Temperature and Intravenous Ondansetron Prophylaxis Reduce Incidence of Post-spinal Shivering in Obstetric Population? A Double-blind, Randomised, Factorial Study. Recruiting NCT04654429 Phase 4 IV Ondansetron 4mg;Placebo
10 Tacrolimus Associated Tremors in Liver Transplant Recipients: a Randomized Open Label Trial Comparing De Novo Extended-release Once Daily (LCP-TAC) and Twice Daily Immediate-release (IR-TAC) Tacrolimus Formulations Not yet recruiting NCT05089604 Phase 4 Tacrolimus, Immediate Release, Oral;Tacrolimus Extended Release Oral Tablet
11 Atlas Predicted DBS Settings in Essential Tremor Terminated NCT02678429 Phase 4
12 Evaluation of Botulinum Toxin Injection Efficacy in the Treatment of Head Essential Tremor by a Multi-center, Randomized, Double-Blind, Parallel-group, Placebo-controlled Study Unknown status NCT02555982 Phase 3 BOTOX ® 200 Unités;Placebo
13 The Single Center, Phase III Clinical Trial to Evaluate the Efficacy and the Safety of [18F]FPCIT Positron Emission Tomography in Parkinson's Disease and Essential Tremor Patients Completed NCT00468078 Phase 3 F-18 FPCIT
14 A Comparison of the Efficacy and Safety of Topiramate Versus Placebo in the Treatment of Essential Tremor Completed NCT00236496 Phase 3 topiramate
15 Novel Therapies for Essential Tremor Completed NCT00018564 Phase 3 treatments for essential tremor
16 Diaphragmatic Breathing and Heart Rate Variability Training for Improving Hypertension in Fragile X Associated Tremor/Ataxia Completed NCT03816540 Phase 3
17 A Multicentre, Phase 3, Clinical Study to Compare the Striatal Uptake of a Dopamine Transporter Radioligand, DaTSCAN™ Ioflupane (123I) Injection, After Intravenous Administration to Chinese Patients With a Diagnosis of Parkinson's Disease, Multiple System Atrophy, Progressive Supranuclear Palsy, or Essential Tremor and to Healthy Controls Completed NCT04193527 Phase 3 DaTSCAN™ Ioflupane (123I) Injection
18 Double-Blind, Randomized, Controlled, Cross-over Comparison of Efficacy and Safety of Botulinum Toxin Type A in the Targeted Treatment of Disabling Tremor in Multiple Sclerosis Completed NCT01018485 Phase 3 Botulinum Toxin Type A
19 Switching Study of Kidney Transplant Patients With Tremor to LCP-Tacro (STRATO) Completed NCT01438710 Phase 3 Prograf;LCP-Tacro
20 Intravenous Dexmedetomidine for Treatment of Shivering During Cesarean Section Under Neuraxial Anesthesia: A Randomized Controlled Trial Completed NCT02384343 Phase 3 Dexmedetomidine;Normal saline
21 Non-inferiority Study of the Molecular Imaging of Dopamine Transporters Using [123I]-FP/CIT-SPECT and [18F] LBT-999-PET to Distinguish Between Parkinson's Disease and Essential Tremor. Recruiting NCT04265209 Phase 3 SPECT;PET
22 Bilateral Essential Tremor Treatment With Gamma Knife Recruiting NCT04748640 Phase 2, Phase 3
23 Central Mechanisms and Treatment Response of Sodium Oxybate in Spasmodic Dysphonia and Voice Tremor Active, not recruiting NCT03292458 Phase 2, Phase 3 Sodium Oxybate
24 A 4 Week, Parallel-Design, Double-Blind, Placebo-Controlled Trial of Gabapentin in the Treatment of Neuroleptic-Induced Tremor: Clinical and Instrumental Ratings of Outcome. Terminated NCT00533455 Phase 3 Gabapentin
25 Efficacy of Pramipexole Extended Release in the Treatment of Essential Tremor: a Double-blind, Cross-over, Placebo-controlled Multicenter Study Withdrawn NCT01441284 Phase 3 pramipexole;placebo
26 Dexmedetomidine Effects on Microelectrode Recording in Deep Brain Stimulation Withdrawn NCT00608231 Phase 2, Phase 3 Dexmedetomidine Hydrochloride Infusion;Normal Saline
27 Botulinum Toxin Type A for Injection of Bilateral Upper Extremity Tremor in Patients With Essential Tremor Using Kinematic Assessment Unknown status NCT02551848 Phase 2 Botulinum toxin type A
28 Use of Kinematic Assessment of Hand Tremor Pre- and Post- Treatment With Botulinum Toxin Type A in Essential Tremor and Parkinson Disease Unknown status NCT02427646 Phase 2 BoNT-A
29 A Double-Blind, Cross-Over, Placebo-Controlled Efficacy and Tolerability Study of Perampanel and Essential Tremor Unknown status NCT02668146 Phase 2 Perampanel;Placebo
30 Kinematic Characterization of Upper Limb Parkinson's Disease Tremor for Optimized Botulinum Toxin Type A Therapy Unknown status NCT02668497 Phase 2 Botulinum Toxin Type A
31 An Evaluation of Effectiveness and Toxicity of CyberKnife Based Functional Radiosurgery for Parkinson Disease Patients Suffering From Tremor and Its Implementation in Poland Unknown status NCT02406105 Phase 2 CyberKnife
32 Effects of Octanoic Acid for Treatment of Essential Voice Tremor Completed NCT01864525 Phase 1, Phase 2 Octanoic acid;Inactive capsule
33 A Phase 2, Double-Blind, Placebo-controlled, Randomized Study Evaluating the Efficacy, Safety, and Tolerability of Sage-324 in the Treatment of Individuals With Essential Tremor Completed NCT04305275 Phase 2 SAGE-324;SAGE-324 Placebo
34 A Double-blind, Placebo-controlled, Two-Period Crossover Proof-of-Concept Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-547 Injection in the Treatment of Patients With Essential Tremor Completed NCT02277106 Phase 2 SAGE-547;Placebo
35 Transcranial Static Magnetic Field Stimulation (tSMS) in Essential Tremor Completed NCT03780426 Phase 2
36 A Double-Blind, Cross-Over, Placebo- Controlled Efficacy and Tolerability Study of Oral Cannabidiol (CBD) and Tetrahydrocannabinol (THC) for Essential Tremor (ET). Completed NCT03805750 Phase 1, Phase 2 CBD/THC;Placebo oral capsule
37 A Phase 2a Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of CAD-1883 Oral Treatment in Adults With Essential Tremor Completed NCT03688685 Phase 2 CAD-1883
38 Double-Blind, Placebo Controlled Pilot-Study of Octanoic Acid in Essential Tremor Completed NCT00848172 Phase 1, Phase 2 Octanoic Acid;Placebo
39 A Phase 2a, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of SAGE-217 in the Treatment of Subjects With Essential Tremor Completed NCT02978781 Phase 2 SAGE-217;Placebo
40 A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of CX-8998 for Essential Tremor Completed NCT03101241 Phase 2 CX-8998;Placebo
41 A Randomized, Double Blind, Placebo-Controlled, Crossover, Proof of Concept Study to Evaluate the Effectiveness and Safety of Carisbamate in the Treatment of Essential Tremor Completed NCT00524056 Phase 2 Carisbamate;Placebo
42 Treatment Efficacy of 1-Octanol Compared to Placebo in Adults With Essential Tremor Completed NCT00080366 Phase 2 1-Octanol
43 Multiple-dose, Double-blind, Placebo-controlled, Crossover Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Sodium Oxybate (Xyrem) in Subjects With Moderate to Severe Essential Tremor Completed NCT00598078 Phase 2 Sodium Oxybate
44 A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of NBI-827104 in Subjects With Essential Tremor Completed NCT04880616 Phase 2 NBI-827104;Placebo
45 Novel Therapies for Essential Tremor - Zonisamide Pilot Study Completed NCT00223743 Phase 2 Zonisamide
46 Clinical Trial Characterizing the Bioavailability of 1-Octanol in Adults With Ethanol-responsive Essential Tremor Completed NCT00102596 Phase 2 1-Octanol
47 Efficacy of Levetiracetam in Patients With Essential Tremor Completed NCT00620165 Phase 1, Phase 2 levetiracetam;placebo
48 A Phase 2 Clinical Trial Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of PRAX-944 in Adults With Essential Tremor Completed NCT05021978 Phase 2 Part A: 20 and 40 mg PRAX-944;Part B: 120 mg PRAX-944;Part B: 120 mg PRAX-944 and Placebo
49 Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Efficacy and Safety of NT 201 in the Unilateral Treatment of Essential Tremor of the Upper Limb Completed NCT02207946 Phase 2 IncobotulinumtoxinA;Placebo
50 A Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Safety, Tolerability and Proof of Concept Study of ST101 for Essential Tremor Completed NCT01332695 Phase 2 ST101;Placebo

Search NIH Clinical Center for Tremor

Genetic Tests for Tremor

Genetic tests related to Tremor:

# Genetic test Affiliating Genes
1 Tremor 28

Anatomical Context for Tremor

Organs/tissues related to Tremor:

MalaCards : Brain, Thyroid, Subthalamic Nucleus, Tongue, Liver, Thalamus, Kidney

Publications for Tremor

Articles related to Tremor:

(show top 50) (show all 21963)
# Title Authors PMID Year
1
Energy threshold changes in volcanic activity at Mt. Etna (Italy) inferred from volcanic tremor. 62 41
36284217 2022
2
Video-Based Hand Movement Analysis of Parkinson Patients before and after Medication Using High-Frame-Rate Videos and MediaPipe. 62 41
36298342 2022
3
The hand tremor spectrum is modified by the inertial sensor mass during lightweight wearable and smartphone-based assessment in healthy young subjects. 62 41
36207392 2022
4
Whole-genome sequencing of patients with rare diseases in a national health system. 5
32581362 2020
5
Neuronal nitric oxide synthase/reactive oxygen species pathway is involved in apoptosis and pyroptosis in epilepsy. 62
36453412 2023
6
Robotic surgery in gynaecology: Scientific Impact Paper No. 71 (July 2022). 62
35844092 2023
7
Time to Symptom Resolution After Total Thyroidectomy for Graves' Disease. 62
36179596 2023
8
Traditional Chinese medicine Pingchan granule for motor symptoms and functions in Parkinson's disease: A multicenter, randomized, double-blind, placebo-controlled study. 62
36283254 2023
9
The Contribution of Neuroimaging to the Understanding of Essential Tremor Pathophysiology: a Systematic Review. 62
34657271 2022
10
Alteration of hippocampal Egr3, GABA A receptors, Il-1β, Il6 and Ccl3 expression in audiogenic tremor mice after seizure. 62
36356419 2022
11
The cost-effectiveness of unilateral magnetic resonance-guided focused ultrasound in comparison with unilateral deep brain stimulation for the treatment of medically refractory essential tremor in England. 62
36125247 2022
12
Holmes tremor: an updated review. 62
36006552 2022
13
DBS, tcMRgFUS, and gamma knife radiosurgery for the treatment of essential tremor: a systematic review on techniques, indications, and current applications. 62
35301835 2022
14
Thalamic Segmentation and Neural Activation Modeling Based on Individual Tissue Microstructure in Deep Brain Stimulation for Essential Tremor. 62
36470728 2022
15
MRI-guided focused-ultrasound thalamotomy in essential tremor: Immediate and delayed changes in cortico-muscular coherence and cortico-cortical out-strength. 62
36283222 2022
16
Sweet spots of standard and directional leads in patients with refractory essential tremor: white matter pathways associated with maximal tremor improvement. 62
35535840 2022
17
The Hidden Burden of Disease and Treatment Experiences of Patients with Essential Tremor: A Retrospective Claims Data Analysis. 62
36239902 2022
18
The factor structure of extrapyramidal symptoms evaluated using the Drug-Induced Extrapyramidal Symptoms Scale in patients with schizophrenia: Results from the 2016 REAP AP-4 study. 62
36462184 2022
19
Intranasal disulfiram-induced encephalopathy: clinical and neuroimage findings. 62
36440748 2022
20
Acute vertical pendular nystagmus: eye-movement analysis and review of the literature. 62
35904591 2022
21
Assessing the impact of MR-guided focused ultrasound thalamotomy on brain activity and connectivity in patients with essential tremor. 62
36455269 2022
22
Zonisamide add-on in tremor-dominant Parkinson's disease- A randomized controlled clinical trial. 62
36323130 2022
23
Thalamo-cortical network is associated with harmaline-induced tremor in rodent model. 62
36007599 2022
24
Retrospective assessment of porcine circovirus 3 (PCV-3) in formalin-fixed, paraffin-embedded tissues from pigs affected by different clinical-pathological conditions. 62
36471405 2022
25
Mental calculation increases physiological postural tremor, but does not influence physiological goal-directed kinetic tremor. 62
36121480 2022
26
Correction to: The Italian tremor Network (TITAN): rationale, design and preliminary findings. 62
35718847 2022
27
Writing tremor in Parkinson's disease: frequency and associated clinical features. 62
36289110 2022
28
Wearable motion sensors to track tremor changes after radiosurgical thalamotomy. 62
35986762 2022
29
Association between postural tremor and risk of disability in community-dwelling older people. 62
36462179 2022
30
Effects of trihexyphenidyl on prefrontal executive function and spontaneous neural activity in patients with tremor-dominant Parkinson's disease: An fNIRS study. 62
36401901 2022
31
Coma, Severe Hypotension, and Pinpoint Pupils After Olanzapine Intoxication in the Intensive Care Unit with Symptom Reversal After Administration of Flumazenil. 62
36451528 2022
32
A multiple-tissue-specific magnetic resonance imaging model for diagnosing Parkinson's disease: a brain radiomics study. 62
35662223 2022
33
Ocular Palatal Tremor With Face "Twitches". 62
34369472 2022
34
Clinical features and reclassification of essential tremor with NOTCH2NLC GGC repeat expansions based on a long-term follow-up. 62
36086903 2022
35
Recent research progress on metabolic syndrome and risk of Parkinson's disease. 62
36450297 2022
36
Clinical and genotypic analysis in determining dystonia non-motor phenotypic heterogeneity: a UK Biobank study. 62
35925398 2022
37
Identification of exosomal biomarkers and its optimal isolation and detection method for the diagnosis of Parkinson's disease: A systematic review and meta-analysis. 62
36273807 2022
38
The International Fragile X Premutation Registry: building a resource for research and clinical trial readiness. 62
35701103 2022
39
Different z-score cut-offs for striatal binding ratio (SBR) of DaT SPECT are needed to support the diagnosis of Parkinson's Disease (PD) and dementia with Lewy bodies (DLB). 62
36471041 2022
40
Childhood Neurologic Conditions: Movement Disorders. 62
36459665 2022
41
Closed loop deep brain stimulation: A systematic scoping review. 62
36356439 2022
42
Classification of Parkinson's disease motor phenotype: a machine learning approach. 62
36335541 2022
43
Frequency of FMR1 Premutation Alleles in Patients with Undiagnosed Cerebellar Ataxia and Multiple System Atrophy in the Japanese Population. 62
34845661 2022
44
SARS-CoV-2/COVID-19 associated pediatric acute-onset neuropsychiatric syndrome a case report of female twin adolescents. 62
36267397 2022
45
The role of sensory feedback from carpal sinus hairs in locomotor kinematics of rats (Rattus norvegicus, Rodentia) during walking on narrow substrates. 62
36423499 2022
46
Brain network characteristics and cognitive performance in motor subtypes of Parkinson's disease: A resting state fMRI study. 62
36332290 2022
47
Lipid profile in Parkinson's disease: The potential role of brain-derived neurotrophic factor. 62
36349606 2022
48
Ellagic acid activates the Keap1-Nrf2-ARE signaling pathway in improving Parkinson's disease: A review. 62
36242848 2022
49
Motor cortical plasticity and its correlation with motor symptoms in Parkinson's disease. 62
36097517 2022
50
Cortical and subcortical morphological alterations in motor subtypes of Parkinson's disease. 62
36470900 2022

Variations for Tremor

ClinVar genetic disease variations for Tremor:

5 (show all 20)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 AGO1 NM_012199.5(AGO1):c.536TCT[1] (p.Phe180del) MICROSAT Pathogenic
521576 rs1553154062 GRCh37: 1:36359296-36359298
GRCh38: 1:35893695-35893697
2 overlap with 3 genes NC_000006.11:g.(117961791_117961792)_(118280043_118280044)del DEL Pathogenic
180225 GRCh37: 6:117961791-118280044
GRCh38: 6:117640628-117958881
3 overlap with 2 genes NC_000006.11:g.(117971549_117971550)_(118218719_118218720)del DEL Pathogenic
180226 GRCh37: 6:117971549-118218720
GRCh38: 6:117650386-117897557
4 overlap with 24 genes NC_000006.11:g.(116681080_116735056)_(119687719_119775014)del DEL Pathogenic
180227 GRCh37: 6:116681080-119775014
GRCh38:
5 C19orf12 NM_031448.6(C19orf12):c.172G>A (p.Gly58Arg) SNV Pathogenic
31157 rs515726205 GRCh37: 19:30193873-30193873
GRCh38: 19:29702966-29702966
6 STXBP1 NM_001032221.6(STXBP1):c.1099C>T (p.Arg367Ter) SNV Pathogenic
207429 rs796053366 GRCh37: 9:130435529-130435529
GRCh38: 9:127673250-127673250
7 C19orf12 NM_031448.6(C19orf12):c.391A>G (p.Lys131Glu) SNV Pathogenic
31158 rs146170087 GRCh37: 19:30193654-30193654
GRCh38: 19:29702747-29702747
8 HARS1 NM_002109.6(HARS1):c.730delG DEL Pathogenic
804286 rs1581505917 GRCh37: 5:140057005-140057005
GRCh38: 5:140677420-140677420
9 HARS1 NM_002109.6(HARS1):c.616G>T (p.Asp206Tyr) SNV Pathogenic
804285 rs1131040 GRCh37: 5:140057507-140057507
GRCh38: 5:140677922-140677922
10 LOC106627981, GBA1 NM_000157.4(GBA1):c.1093G>A (p.Glu365Lys) SNV Risk Factor
199044 rs2230288 GRCh37: 1:155206167-155206167
GRCh38: 1:155236376-155236376
11 TMEM67 NM_153704.6(TMEM67):c.1843T>C (p.Cys615Arg) SNV Likely Pathogenic
1383 rs201893408 GRCh37: 8:94808198-94808198
GRCh38: 8:93795970-93795970
12 TMEM67 NM_153704.6(TMEM67):c.1321C>T (p.Arg441Cys) SNV Likely Pathogenic
217725 rs752362727 GRCh37: 8:94798483-94798483
GRCh38: 8:93786255-93786255
13 MPZ NM_000530.8(MPZ):c.699T>G (p.Ser233Arg) SNV Likely Pathogenic
374017 rs1057518839 GRCh37: 1:161275714-161275714
GRCh38: 1:161305924-161305924
14 FIG4 NM_014845.6(FIG4):c.904G>A (p.Glu302Lys) SNV Likely Pathogenic
156015 rs587777714 GRCh37: 6:110064340-110064340
GRCh38: 6:109743137-109743137
15 MT-ATP6 NC_012920.1(MT-ATP6):m.9032T>C SNV Likely Pathogenic
693061 rs1603221994 GRCh37: MT:9032-9032
GRCh38: MT:9032-9032
16 CACNA1H NM_021098.3(CACNA1H):c.6884C>T (p.Ser2295Phe) SNV Uncertain Significance
523531 rs772718469 GRCh37: 16:1270816-1270816
GRCh38: 16:1220816-1220816
17 ADGRV1 NM_032119.4(ADGRV1):c.5188A>T (p.Ile1730Phe) SNV Uncertain Significance
523543 rs1554079046 GRCh37: 5:89971137-89971137
GRCh38: 5:90675320-90675320
18 TBC1D24 NM_001199107.2(TBC1D24):c.920A>G (p.Asn307Ser) SNV Uncertain Significance
583333 rs761934676 GRCh37: 16:2547069-2547069
GRCh38: 16:2497068-2497068
19 GLI2 NM_001374353.1(GLI2):c.2593A>T (p.Thr865Ser) SNV Uncertain Significance
523482 rs1332140763 GRCh37: 2:121746134-121746134
GRCh38: 2:120988558-120988558
20 SYNE1 NM_182961.4(SYNE1):c.25015G>T (p.Gly8339Cys) SNV Uncertain Significance
983391 rs747768163 GRCh37: 6:152464862-152464862
GRCh38: 6:152143727-152143727

Copy number variations for Tremor from CNVD:

6
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 247217 9 129375646 129461836 Deletion NIBAN2 Tremor
2 247222 9 129375646 129461836 Deletion STXBP1 Tremor

Expression for Tremor

Search GEO for disease gene expression data for Tremor.

Pathways for Tremor

Pathways related to Tremor according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.89 STXBP1 SNCA PRKN LRRK2 FMR1
2 10.38 SNCA PRKN LRRK2

GO Terms for Tremor

Cellular components related to Tremor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 postsynapse GO:0098794 9.56 STXBP1 SNCA LRRK2 FMR1
2 presynaptic cytosol GO:0099523 9.33 STXBP1 LRRK2
3 cell projection GO:0042995 9.28 TMEM67 TENM4 SNCA PRKN LRRK2 FMR1

Biological processes related to Tremor according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of neuron apoptotic process GO:0043524 10.11 STXBP1 SNCA PRKN GBA1
2 autophagy GO:0006914 10.02 PRKN LRRK2 GBA1 DRD3 C19orf12
3 regulation of dopamine secretion GO:0014059 9.93 SNCA PRKN DRD3
4 amyloid fibril formation GO:1990000 9.88 FUS PRKN SNCA
5 negative regulation of neuron death GO:1901215 9.86 SNCA PRKN LRRK2 GBA1
6 cellular response to manganese ion GO:0071287 9.84 PRKN LRRK2
7 protein localization to mitochondrion GO:0070585 9.83 PRKN LRRK2
8 dopamine uptake involved in synaptic transmission GO:0051583 9.8 SNCA PRKN
9 positive regulation of dopamine receptor signaling pathway GO:0060161 9.78 LRRK2 DRD3
10 regulation of synaptic vesicle transport GO:1902803 9.73 PRKN LRRK2
11 regulation of neurotransmitter secretion GO:0046928 9.62 SNCA PRKN FMR1
12 regulation of synaptic vesicle endocytosis GO:1900242 9.55 PRKN LRRK2
13 dopamine metabolic process GO:0042417 9.55 SNCA PRKN DRD3
14 synaptic transmission, dopaminergic GO:0001963 9.26 SNCA PRKN DRD3
15 regulation of locomotion GO:0040012 9.02 SNCA LRRK2 DRD3

Molecular functions related to Tremor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 SNARE binding GO:0000149 9.1 STXBP1 SNCA LRRK2

Sources for Tremor

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....